| web: | mayocliniclabs.com |
|---|---|
| email: | mcl@mayo.edu |
| telephone: | 800-533-1710 |
| 国际的： | +1 855-379-3115 |
| 值仅在打印当天有效 | |
测试ID：弗尔迪格
digoxin, Free, Serum
对...有用
suggests clinical disorders or settings where the test may be helpful
suggests clinical disorders or settings where the test may be helpful
评估肾脏中的重现（突破）地高辛毒性
评估对施用更多抗二高毒素的需求
deciding when to reintroduce digoxin therapy
monitoring patients with possible digoxin-like immunoreactive factors (DLIFs)
方法名称
一种short description of the method used to perform the test
一种short description of the method used to perform the test
超滤，然后进行电化学发光免疫测定
纽约州可用
我ndicates the status of NY State approval and if the test is orderable for NY State clients.
我ndicates the status of NY State approval and if the test is orderable for NY State clients.
是的
报告名称
列出了测试的已发布名称的缩写或缩写版本
列出了测试的已发布名称的缩写或缩写版本
digoxin, Free, S
specimen Type
描述了测试验证的样品类型
描述了测试验证的样品类型
血清
specimen Required
defines the optimal specimen required to perform the test and the preferred volume to complete testing
defines the optimal specimen required to perform the test and the preferred volume to complete testing
病人准备：在标本收集之前12小时没有take multivitamins or dietary supplements containing biotin (vitamin B7), which is commonly found in hair, skin, and nail supplements and multivitamins.
容器/管：
首选：血清凝胶
可接受：红色顶部
specimen Volume:1 mL
收集说明：
1.在最后剂量的地高辛6到8小时吸血。
2。血清凝胶tubes should be centrifuged within 2 hours of collection.
3.红色顶管应离心，并在收集后2小时内将血清等分等分。
形式
标本最小体积
定义由测试实验室确定的提供临床相关结果所需的样品数量
定义由测试实验室确定的提供临床相关结果所需的样品数量
0.6毫升
拒绝due To
标识可能导致样品被拒绝的样品类型和条件
标识可能导致样品被拒绝的样品类型和条件
| 严重的溶血 | 拒绝 |
标本稳定性信息
provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included
provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included
| specimen Type | temperature | 时间 | 特殊容器 |
|---|---|---|---|
| 血清 | refrigerated (preferred) | 7 days | |
| Frozen | 180 days |
对...有用
suggests clinical disorders or settings where the test may be helpful
suggests clinical disorders or settings where the test may be helpful
评估肾脏中的重现（突破）地高辛毒性
评估对施用更多抗二高毒素的需求
deciding when to reintroduce digoxin therapy
monitoring patients with possible digoxin-like immunoreactive factors (DLIFs)
Clinical Information
discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
地高辛是一种广泛处方的心脏药物，具有狭窄的治疗窗口（治疗和有毒组织浓度之间存在很小的差异）。虽然多余的地高辛可能会产生严重的副作用（例如，心脏心律失常，心力衰竭，癫痫发作，死亡），但它是可获得抗衰竭治疗的少数治疗药物之一。（1）在有毒情况下，抗体碎片疗法，涉及抗体片段治疗指示了地高辛抗体（例如Digibind，地高辛免疫FAB）的抗体。在制造digibind时，木瓜蛋白酶将高氧蛋白特异性IgG抗体切割成2个抗原结合位点片段（FAB片段）。这些片段与地高辛结合，阻断地高辛分子的活性位点，使其无法获得其受体分子和生物学无活性。然后，肾脏排泄Fab碎片二唑素复合物。
给药Fab片段后，血液中的二高氧蛋白浓度增加了约10至30倍。另一方面，负责其药理活性的未结合（自由）分数减少。免疫测定（例如，挖掘 /地高辛，血清）进行的传统地高辛测定法测量Fab片段结合（不活跃）地高辛和游离（活性）地高辛（IE，总地高辛），并且不适合在地高毒素特异性Fab Fab片段时管理患者治疗已经进行。在这种情况下，仅需要测量游离地高辛水平的测定。
肾脏提供了从身体消除Fab碎片的主要途径。在肾功能正常的患者中，尿道特异性FAB片段在尿液中排出，生物半衰期为15至20小时。通常，在开始进行FAB碎片疗法后，在半小时或更少的时间内开始了地高辛中毒的体征或症状的改善。肾衰竭患者可能会延迟清除。在此类患者中，如果先前结合的药物从FAB片段中释放出来，则可能会复发毒性，从而导致游离地高辛水平升高。
地高氧蛋白样免疫反应因子（DLIF）是内源性物质，可以与某些地高辛免疫测定中使用的抗体进行交叉反应，从而导致错误的结果。在某些体积膨胀的患者（例如新生儿，肾脏或肝病患者）以及第三个妊娠中期女性接受地高辛治疗的女性中，可以看到DLIF。在测试之前删除。
提供以下订购指南：
- 当肌酐清除率少于30 mL/min/表面积时：每天订购免费地高辛水平12天（或直到解雇）
- 当肌酐清除等于或以上等于或高于30 mL/min/catural/表面积（并且患者不接受肾脏替代疗法）：每天每天订购自由水平72小时，只要最后一个水平不在预计有良好的清除率和较低的重新毒性风险）
-同样，在上述时间段内每隔一天订购每隔一天的地高辛水平，目的是确定自由度变化和总级别之间是否存在相关性。
reference Values
describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
<16岁：
尚未针对16岁以下的患者建立治疗范围。在成年人中，建议的无血清二高氧蛋白治疗范围为0.4-0.9 ng/ml。
有毒浓度：> OR = 3.0
> or =16 years:
0.4-0.9 ng/mL
有毒浓度：> OR = 3.0 ng/ ml
解释
provides information to assist in interpretation of the test results
provides information to assist in interpretation of the test results
目标治疗水平为0.4至0.9 ng/ml。当游离地高辛浓度为3.0 ng/ml或更高时，可以看到毒性。小儿患者可以忍受较高的浓度。
由于测定中蛋白质结合的地高辛的分离，游离地高辛的治疗浓度比总地高辛的治疗值低25％。
Cautions
讨论可能导致诊断混乱的条件，包括不正确的标本收集和处理，不适当的测试选择以及干扰物质
讨论可能导致诊断混乱的条件，包括不正确的标本收集和处理，不适当的测试选择以及干扰物质
patients vary in their responsiveness to digoxin.
肾功能障碍改变地高辛和抗体结合地高辛的代谢。
地高辛给药后需要6到8个小时才能在血清和组织之间平衡。在最后剂量的地高辛剂后不到6到8小时收集的标本获得的结果应谨慎解释。
digibind (Glaxo Wellcome, Research Triangle Park, NC) is the most common brand of antidigoxin Fab fragments used; other brands are available and may be monitored by this assay.
Clinical Reference
recommendations for in-depth reading of a clinical nature
recommendations for in-depth reading of a clinical nature
1。JORTANI SA，PINAR A，JOHNSON NA，VALDES R JR：在存在解毒剂（Digibind）的情况下通过免疫测定方法未结束的地高辛测量的有效性。Clin Chim Acta。1999; 283：159-169
2。d我G我b我nddigoxin Immune FAB (Ovine). Package insert. GlaxoSmithKline; 2003
3。moyer TP, Boeckx RL, eds: Applied Therapeutic Drug Monitoring. Vol 2. American Association for Clinical Chemistry Press; 1984
4. Jortani SA, Voldes R Jr: Digoxin and its related endogenous factors.Crit Rev Clin Lab Sci。1997; 34：225-274
5. Datta P, Hinz V, Klee G: Comparison four digoxin immunoassays with respect to interference from digoxin-like immunoreactive factors. Clin Biochem. 1996;29(6):541-547
6。soldin SJ: Free drug measurements. When and why? An overview. Arch Pathol Lab Med. 1999;123:822-823
7. Dickstein K，Cohen-Solal A，Filippatos G等：ESC诊断和治疗急性和慢性心力衰竭的指南2008：欧洲社会急性和慢性心力衰竭的诊断和治疗工作队2008心脏病学。Eur Heart J. 2008; 29：2388-2442
8。Milone MC，Shaw LM：治疗药物及其管理。在：Rifai N，Horvath AR，Wittwer Ct，编辑。Tietz临床化学和分子诊断教科书第六版。Elsevier;2018800-831
方法描述
describes how the test is performed and provides a method-specific reference
describes how the test is performed and provides a method-specific reference
自由地高辛与高地高辛特异性结合抗体片段，不与蛋白质结合，与结合地高辛分开by a 30-kD centrifugal filter device. Free digoxin passes through the filter; bound digoxin is retained in the filter. The filtrate is analyzed for digoxin using一种采用针对地高辛的单克隆抗体的竞争性电化学免疫测定。试样中的地高辛与五烯基化抗体复合物上的结合位点标记的添加的地高辛衍生物竞争。添加链霉亲和素涂层的微粒，并将混合物吸入测量细胞中，在该细胞中将微粒被磁捕获到电极表面上。在电极上的电压施加会诱导化学发光发射，然后测量。(Package insert: Elecsys Digoxin, Roche Diagnostics; V3.0, 11/2019)
pdFreport
指示该报告是否包含带有图表，图像或其他丰富信息的其他文档
指示该报告是否包含带有图表，图像或其他丰富信息的其他文档
no
day(s) Performed
概述了进行测试的日子。该领域反映了样品必须在测试实验室中才能开始测试过程的一天，并包括进行测试之前的任何标本准备和处理时间。一些测试被列为连续执行的，这意味着测定在白天多次执行。
概述了进行测试的日子。该领域反映了样品必须在测试实验室中才能开始测试过程的一天，并包括进行测试之前的任何标本准备和处理时间。一些测试被列为连续执行的，这意味着测定在白天多次执行。
星期一至周日
可用报告
the interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.
the interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.
同一天/1天
specimen Retention Time
outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
7 days
performing Laboratory Location
指示执行测试的实验室的位置
指示执行测试的实验室的位置
罗切斯特
Fees
几个因素决定了进行测试的费用。请与您的美国或国际区域经理联系，以获取有关建立费用时间表的信息，或了解有关资源以优化测试选择的更多信息。
几个因素决定了进行测试的费用。请与您的美国或国际区域经理联系，以获取有关建立费用时间表的信息，或了解有关资源以优化测试选择的更多信息。
test Classification
provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.
provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.
this test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.
CPT代码信息
为确定每个测试或配置文件的适当当前程序术语（CPT）代码提供指导。列出的CPT代码反映了Mayo Clinic实验室对CPTbetway中国版编码要求的解释。每个实验室的责任是确定用于计费的正确CPT代码。
CPT代码由表演实验室提供。
为确定每个测试或配置文件的适当当前程序术语（CPT）代码提供指导。列出的CPT代码反映了Mayo Clinic实验室对CPTbetway中国版编码要求的解释。每个实验室的责任是确定用于计费的正确CPT代码。
CPT代码由表演实验室提供。
CPT代码由表演实验室提供。
80163
loinc®信息
| 测试ID | 测试订单名称 | 订单loinc值
provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.
|
|---|---|---|
| 弗尔迪格 | digoxin, Free, S | 3562-6 |
| 结果ID | test Result Name | result LOINC Value
一种pplies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
|---|---|---|
| 弗尔迪格 | digoxin, Free, S | 3562-6 |
测试设置资源
setup Files
test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.
test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.
样本报告
提供正常和异常样本报告作为报告外观的参考。
提供正常和异常样本报告作为报告外观的参考。
SI样本报告
国际的system (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.
国际的system (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.